This is an excerpt from our whitepaper, “Evolving Pharmaceutical Market Access in Brazil: How the Latest Developments Will Change your Business Strategy”. To read the full paper, please click here.
With expectations to reach 30% of the nearly $1.2 trillion US global spend, and
50-70% of the $70 billion annual US growth forecasted in the pharmaceutical
sector by 2016, it is clear why emerging markets are considered the new
frontier. They are the new hope for a pharmaceutical industry that is seeking
new strategies and partnerships to balance the stagnation in more mature
Quickly growing, increasingly competitive, culturally, socially and economically diverse, emerging markets defy the effectiveness of a uniform approach and call for local business planning based on a comprehensive and global perspective. For this reason, international pharmaceutical companies must be willing to implement market-specific strategies and local thinking within their global business strategy. Nevertheless evolving political stances, increasing international competition, and rising local manufacturers are toughening market access environments and creating new, and sometimes unexpected, risks for drug makers.
Brazil is one of many examples showing how quickly business conditions for drug makers are changing and how important it is to identify, evaluate, and foresee such changes as early as possible to improve and consolidate market positioning. This paper provides an overview of latest trends regarding pharmaceutical taxation, strategic partnerships and generics promotion.
Latest Reforms and New Challenges
With over $220 billion of healthcare expenditure, a strong economic growth, and drug prices adjusted annually (2.7-6.31% increase estimated in 2013), Brazil is destined to become the third largest pharmaceutical market by 2020 after US and China.
Despite its strong economic growth, Brazil is facing increasing pressure to control healthcare expenditure and, at the same time, to promote innovation and improve access to healthcare.
Pursuing this difficult task, decision makers are discussing several initiatives, some of them already converted into law, which will reshape the pharmaceutical market in the following years. In a context of increasing competition and stricter regulatory hurdles, Brazil will become a much more challenging business environment.
To read more, please click here to download the white paper.